Applications of N-(2'-Cyanobiphenyl-4-ylmethyl)-L-valine Methyl Ester Hydrochloride in Industrial Manufacturing

As a dedicated manufacturer of N-(2'-Cyanobiphenyl-4-ylmethyl)-L-valine Methyl Ester Hydrochloride, we ensure our material meets the specialized requirements of advanced organic synthesis, supporting innovation in targeted industrial segments. Below we outline practical application scenarios based on verified, large-scale usage in downstream sectors.

1. Pharmaceutical Intermediate for Angiotensin Receptor Blocker (ARB) Synthesis

This material acts as a core intermediate in the synthesis of specific sartans, a class of antihypertensive drugs. Production teams use it during key amidation and methylation stages to construct biphenyl-tetrazole structures. Strict regulatory expectations govern each step, from sourcing to final purification, to maintain product consistency for active pharmaceutical ingredients (APIs).

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• Current Good Manufacturing Practices (cGMP) – US FDA 21 CFR Part 211
• European Pharmacopoeia Monographs
• ICH Q3A/B Impurity Guidelines

Typical usage ratio

• Employed at a 0.8–1.1 molar equivalent relative to downstream amide coupling counterparts, tuning according to the targeted drug molecule and desired purity profile.

Downstream process integration

• Precision addition takes place after biphenyl precursor formation, preceding the key coupling or cyclization, and typically followed by HPLC-guided purification.

Final product types

• Angiotensin II receptor blockers (e.g., Valsartan bulk API, Losartan intermediates)
• Pharmaceutical-grade intermediates for further API synthesis

2. Chiral Building Block for Peptidomimetic Compound Manufacturing

This compound’s chiral structure provides a valuable asymmetrical carbon center for the synthesis of peptidomimetics, which find essential roles in drug discovery and small-molecule library projects. Laboratories and production lines rely on the compound for enantioselective assembly, ensuring chirality transfer during multi-step peptide analog synthesis.

Industry compliance standards

• USP General Chapters <823> and <1121> for Synthesis and Quality Control
• ISO 9001:2015 Quality Management for chemical intermediates
• OECD Guidelines for chemical testing and purity analysis

Typical usage ratio

• Incorporated at 5–15% w/w in library synthesis batches; ratios fluctuate with target sequence complexity and chirality requirements.

Downstream process integration

• Blending occurs after initial O-protection and esterification, with the raw material introduced during solid-phase or solution-phase peptide assembly, followed by side-chain deprotection and crystallization.

Final product types

• Peptidomimetic research compounds
• Lead drug candidates for pharmaceutical R&D screening pipelines

3. Key Intermediate in Liquid Crystal Precursor Synthesis

This specialty intermediate advances the precision synthesis of mesogenic cores, essential for high-performance liquid crystal materials. Production lines employ it in specific Grignard reactions and Suzuki couplings, forming cyanobiphenyl structures optimized for use in advanced LC display component production, with strict attention to purity and geometric isomer content.

Industry compliance standards

• ISO 9001:2015 Quality Assurance for advanced materials
• REACH Registration, Evaluation, Authorisation and Restriction of Chemicals (EU Regulation)
• IEC 61249-2-45 Hazardous Substance Restrictions for electronics

Typical usage ratio

• Utilized at 0.5–1.0 molar equivalent in the coupling reactions, strictly controlled by targeted mesogen yield and downstream compatibility requirements.

Downstream process integration

• Integrated following biphenyl framework assembly, during the introduction of cyano groups and subsequent methylation to achieve proper molecular orientation for liquid crystal properties.

Final product types

• Mesogen intermediates for display panels
• Specialty liquid crystal mixtures for electronic displays and optical filters

4. Precursor for Advanced Organic Synthesis in Chemical Research

Synthetic laboratories engaged in medicinal chemistry select this chiral intermediate for constructing complex organic molecules, especially where cyanobiphenyl motifs enable unique receptor-binding attributes. Custom synthesis projects leverage its stability during multi-step derivatization, often as a foundational block to introduce chirality and aromaticity simultaneously.

Industry compliance standards

• ISO/IEC 17025 Testing and Calibration Laboratory Requirements
• GLP (Good Laboratory Practice, OECD Principles)
• GHS (Globally Harmonized System) Safety and Hazard Communication

Typical usage ratio

• Used at variable loadings, typically from 1–20 mmol per reaction scale, depending on the complexity of the synthetic route and the number of stages requiring this motif.

Downstream process integration

• Introduced during early-stage synthetic planning — after parent core construction but before terminal functionalization or salt conversion; monitored by NMR and chromatographic integrity checks.

Final product types

• Pharmaceutical research compounds
• High-value reference standards for analytical method development
• Custom reagents for academic and industrial research

5. Component for Synthesis of Functionalized Aromatic Polymers

Downstream users engaged in specialty polymer development utilize this intermediate for the incorporation of cyano-substituted biphenyl units into polymer backbones. The resulting materials exhibit targeted thermal, dielectric, and mechanical properties, serving niche electronic, coating, and engineering plastic needs. Critical control of monomer feed ratios and processing conditions ensure product reliability.

Industry compliance standards

• ISO 14001:2015 Environmental Management for chemical manufacturing
• ASTM D4000 Standard Classification System for Polymers
• RoHS (Restriction of Hazardous Substances Directive for electronics)

Typical usage ratio

• Blending at 1–10% w/w in copolymerization runs, with the actual ratio determined by target end-use performance criteria and compatibility with co-monomers.

Downstream process integration

• Mixed into the main reaction vessel during the co-polymerization stage, following catalyst and initiator introduction, and before final polymer curing or extrusion.

Final product types

• Specialty polymers for electronic substrates
• Engineered polymer films with enhanced dielectric properties
• Functional coatings for industrial applications